Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Propanc Biopharma Inc (PPCB)

Propanc Biopharma Inc (PPCB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,308
  • Shares Outstanding, K 688,671
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,760 K
  • 60-Month Beta 2.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade PPCB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.01
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 10/20/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0016 +18.75%
on 09/09/20
0.0038 -50.00%
on 09/17/20
-0.0005 (-20.83%)
since 09/01/20
3-Month
0.0013 +46.15%
on 07/24/20
0.0041 -53.66%
on 07/28/20
-0.0018 (-48.65%)
since 07/01/20
52-Week
0.0013 +46.15%
on 07/24/20
1.7500 -99.89%
on 01/02/20
-0.9781 (-99.81%)
since 10/01/19

Most Recent Stories

More News
Propanc Biopharma Provides Shareholder Update

Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today...

PPCB : 0.0018 (-5.26%)
How Propanc Biopharma Is Joining the Fight with Cancer Patients Who Are Increasingly Vulnerable to the COVID-19 Global Pandemic

--Novel Cancer Treatments that Support Immune Function Likely to See Rapid Uptake

PPCB : 0.0018 (-5.26%)
Propanc Biopharma Receives First Allowance for Key Patent Family from Australian Patent Office

Propanc Biopharma, Inc. (OTC:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today...

PPCB : 0.0018 (-5.26%)
Propanc Biopharma Enters Into a $3 Million Financing with Institutional Investor

Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today...

PPCB : 0.0018 (-5.26%)
Propanc Biopharma's Scientific Advisory Board Member Promoted to Professorship Position at Jaen University, Spain

Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today...

PPCB : 0.0018 (-5.26%)
Propanc Biopharma Receives Advance Overseas Finding from Innovation and Science Australia

Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today...

PPCB : 0.0018 (-5.26%)
Propanc Biopharma Advances POP1 Drug Discovery Program

Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today...

PPCB : 0.0018 (-5.26%)
Propanc Biopharma Provides Shareholder Update and Forecast for 2020

Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today...

PPCB : 0.0018 (-5.26%)
Propanc Biopharma Illustrates Novel Mode of Action of PRP, Suppressing EMT Pathways and Metastasis in Cancer Patients

Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today...

PPCB : 0.0018 (-5.26%)
Propanc Biopharma Receives Granted US Patent Covering Additional Composition Claims for PRP

Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that it has received...

PPCB : 0.0018 (-5.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

2nd Resistance Point 0.0026
1st Resistance Point 0.0022
Last Price 0.0018
1st Support Level 0.0016
2nd Support Level 0.0014

See More

52-Week High 1.7500
Fibonacci 61.8% 1.0820
Fibonacci 50% 0.8756
Fibonacci 38.2% 0.6693
Last Price 0.0018
52-Week Low 0.0013

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar